JF
NKTR icon

Jump Financial’s Nektar Therapeutics NKTR Stock Holding History

Jump Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.49M Buy
107,351
+29,949
+39% +$2.19M 0.06% 353
2026
Q1 		$5.57M Buy
77,402
+24,190
+45% +$1.38M 0.07% 324
2025
Q4 		$2.25M Buy
+53,212
New +$2.98M 0.03% 630
2023
Q2 		– Sell
-1,320
Closed -$13.9K – 2042
2023
Q1 		$13.9K Buy
+1,320
New +$39.9K ﹤0.01% 1510
2022
Q4 		– Sell
-9,293
Closed -$446K – 1882
2022
Q3 		$446K Sell
9,293
-2,278
-20% -$136K 0.02% 943
2022
Q2 		$659K Buy
11,571
+9,328
+416% +$589K 0.03% 732
2022
Q1 		$181K Buy
+2,243
New +$332K 0.01% 1326
2021
Q2 		– Sell
-1,567
Closed -$470K – 1298
2021
Q1 		$470K Buy
+1,567
New +$488K 0.04% 421

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jump Financial's NKTR Position: Q2 2026 in Review

Jump Financial increased its Nektar Therapeutics (NKTR) stake by 39% in Q2 2026, buying an estimated $2.19M and bringing the position to 107,351 shares worth $7.49M. The position accounts for 0.06% of the portfolio, ranked #353.

Jump Financial first reported a position in NKTR in Q1 2021 and has held it in 8 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Jump Financial held 107,351 shares of Nektar Therapeutics worth $7.49M as of Q2 2026.
  • Jump Financial bought 29,949 Nektar Therapeutics shares in Q2 2026, an estimated $2.19M.
  • Nektar Therapeutics made up 0.06% of Jump Financial's portfolio in Q2 2026, its #353 holding.
  • Jump Financial first reported a position in Nektar Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.